MedTrace Logo

TBE (Tick-borne Encephalitis) Vaccination in Allergic Patients

NCT02511535 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 119

Last updated 2019-10-25

Study results available
· View outcomes & findings →

Summary

Allergic patients especially those undergoing de-sensitization treatment have an altered immune responsiveness. The investigators aim to find out whether this influences immune responses to primary and booster vaccinations.

Conditions

  • Vaccine Responsiveness in Allergy
  • Vaccine Responsiveness During Allergy De-sensitization Treatment

Interventions

BIOLOGICAL

TBE booster vaccination

Sponsors & Collaborators

  • Medical University of Vienna

    lead OTHER

Principal Investigators

  • Ursula Wiedermann, MD, PhD · Medical University Vienna

Study Design

Allocation
NON_RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2013-09-30
Primary Completion
2016-02-29
Completion
2016-09-30

Countries

  • Austria

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02511535 on ClinicalTrials.gov